Work

Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.9066

Authors: Alice Tsang Shaw, Pasi A. Janne, Benjamin Besse, Benjamin J. Solomon, Fiona Helen Blackhall, D. Ross Camidge, Tony Mok, Vera Hirsh, Judith Robin Scranton, Anna Polli, Yiyun Tang, Keith D. Wilner, Dong-Wan Kim

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Institut Gustave Roussy, Fondation Gustave Roussy, Peter MacCallum Cancer Centre, University of Manchester, The Christie Hospital, Chinese University of Hong Kong, Royal Victoria Hospital, McGill University, Pfizer (United States), Seoul National University Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2494021322

Cites:

Cited by: 12

Related to: 10